标题
VEGF Inhibition, Hypertension, and Renal Toxicity
作者
关键词
-
出版物
Current Oncology Reports
Volume 14, Issue 4, Pages 285-294
出版商
Springer Nature
发表日期
2012-04-28
DOI
10.1007/s11912-012-0242-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Systemic and Kidney Toxicity of Intraocular Administration of Vascular Endothelial Growth Factor Inhibitors
- (2011) Gaëlle Pellé et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction
- (2011) Sachin Gupta et al. ANTI-CANCER DRUGS
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
- (2011) P Österlund et al. BRITISH JOURNAL OF CANCER
- Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib
- (2011) Jenny J. Kim et al. CANCER
- Mechanisms of Antiangiogenic-Induced Arterial Hypertension
- (2011) Jean-Jacques Mourad et al. CURRENT HYPERTENSION REPORTS
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration
- (2011) K. Stylianou et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
- (2010) Michael L. Maitland et al. JNCI-Journal of the National Cancer Institute
- Biology of Anti-Angiogenic Therapy–Induced Thrombotic Microangiopathy
- (2010) Vera Eremina et al. SEMINARS IN NEPHROLOGY
- Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor
- (2009) B. I. Levy ANNALS OF ONCOLOGY
- Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
- (2009) P. Bono et al. ANNALS OF ONCOLOGY
- Hypertension as a surrogate marker for the activity of anti-VEGF agents
- (2009) O. Mir et al. ANNALS OF ONCOLOGY
- Management of hypertension in angiogenesis inhibitor-treated patients
- (2009) H. Izzedine et al. ANNALS OF ONCOLOGY
- Reversibility of capillary density after discontinuation of bevacizumab treatment
- (2009) N. Steeghs et al. ANNALS OF ONCOLOGY
- Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
- (2009) A. Ravaud et al. ANNALS OF ONCOLOGY
- VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
- (2009) Hassane Izzedine et al. EUROPEAN JOURNAL OF CANCER
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
- (2009) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors
- (2009) Marlies H.G. Langenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects
- (2009) Mariëtte HW Kappers et al. JOURNAL OF HYPERTENSION
- Adverse effects of anticancer agents that target the VEGF pathway
- (2009) Helen X. Chen et al. Nature Reviews Clinical Oncology
- Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy
- (2009) O. Costero et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma
- (2009) Vincent Launay-Vacher et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor
- (2008) N. Steeghs et al. CLINICAL CANCER RESEARCH
- Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
- (2008) Nilofer S. Azad et al. JOURNAL OF CLINICAL ONCOLOGY
- A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib
- (2008) T. V. Patel et al. JNCI-Journal of the National Cancer Institute
- Glomerular disease related to anti-VEGF therapy
- (2008) M. Barry Stokes et al. KIDNEY INTERNATIONAL
- Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
- (2008) Shenhong Wu et al. LANCET ONCOLOGY
- Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib
- (2008) G. Bollee et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- VEGF Inhibition and Renal Thrombotic Microangiopathy
- (2008) Vera Eremina et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
- (2007) J.-J. Mourad et al. ANNALS OF ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started